NFKB1 and prostate carcinoma: Interestingly, RYK upregulation was also reported in DU-145 prostate cancer cells in response to the anti-estrogen ICI 182,780, reflecting ER-β/Nf-κB signaling cross-talk and the presence of a cis-acting NF-κB binding element in the promoter region of RYK [130].